Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody (Q28239475)

Stefan Pusch

7

0 references

Felix Sahm

Felix Sahm

4

0 references

Matthias Preusser

Matthias Preusser

2

0 references

David Capper

1

David Capper

0 references

Antje Habel

3

Antje Habel

0 references

Gunhild Mechtersheimer

8

Gunhild Mechtersheimer

0 references

author name string

Ulrike Ackermann

5

0 references

Genevieve Schindler

6

0 references

Hanswalter Zentgraf

describes a project that uses

9

0 references

language of work or name

English

0 references

publication date

July 2011

0 references

published in

Acta Neuropathologica

0 references

volume

122

0 references

issue

1

0 references

page(s)

11-9

0 references

1 reference

Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Targeting BRAF for patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Recurrent BRAF mutations in Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Monoclonal antibody specific for IDH1 R132H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Feasibility of archival non-buffered formalin-fixed and paraffin-embedded tissues for PCR amplification: an analysis of resected gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-011-0841-Z